The US FDA’s Center for Drug Evaluation and Research is consolidating oversight and coordination of all internal and external artificial intelligence efforts into one centralized entity.
Artificial Intelligence: CDER’s New Council Takes Charge Of Oversight, Coordination
The Artificial Intelligence Council takes over work that three different entities in the US FDA’s drugs center had been performing. The new, centralized entity will develop and promote consistency in AI-related activities and advance innovative uses.